TY - JOUR
T1 - The AMCP Format for Formulary Submissions
T2 - Welcome to version 4.0
AU - The AMCP Format Executive Committee
AU - Lee, Jeff
AU - Penna, Pete
AU - Saverno, Kim
AU - Tam, Iris
AU - Daniel Allen, J.
AU - Avey, Steven G.
AU - Brixner, Diana
AU - Lin, Vincent W.
AU - Malone, Daniel C.
AU - Mcelwee, Newell
AU - Pannier, Alan
AU - Sampsel, Elizabeth R.
AU - Sherman, Helen
AU - Watkins, John
AU - White, Jeffrey
AU - Oh, Susan
AU - Nishida, Lynn
N1 - Publisher Copyright:
© 2016, Academy of Managed Care Pharmacy.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Managed care pharmacists are increasingly presented with complex considerations related to prescription drug formulary management. As prescription drug spending soars, and new effective, but expensive drugs rush to the market, pharmacists and other health care decision makers must evaluate a myriad of important clinical and economic considerations in determining the relative value and, subsequently, the appropriate placement of a product within a formulary. The AMCP Format for Formulary Submissions, Version 4.0, is the next iteration of the Format, which was first released in 2000. Version 4.0, developed by pharmacists from health plan, manufacturer, and academic perspectives, provides updated recommendations on acquiring and evaluating clinical and economic evidence to inform formulary and medical policy decisions. It also includes new guidance related to emerging special topic considerations such as biosimilars, specialty pharmacy products, and companion diagnostic tests. Version 4.0 has been modified to improve the usability of the Format, with clarifying guidance related to logistical considerations such as a recommended time frame for implementation of Version 4.0, as well as dossier updates and ongoing communication between manufacturers and health care decision makers. The Format should be used as a framework for ongoing evidencebased dialogue between manufacturers and payers. The evolving health care landscape will require new levels of collaboration and communication among key stakeholders to successfully navigate the challenges of this new environment. The Format provides a framework to support these critical interactions related to product value by facilitating an evidence-based, transparent approach.
AB - Managed care pharmacists are increasingly presented with complex considerations related to prescription drug formulary management. As prescription drug spending soars, and new effective, but expensive drugs rush to the market, pharmacists and other health care decision makers must evaluate a myriad of important clinical and economic considerations in determining the relative value and, subsequently, the appropriate placement of a product within a formulary. The AMCP Format for Formulary Submissions, Version 4.0, is the next iteration of the Format, which was first released in 2000. Version 4.0, developed by pharmacists from health plan, manufacturer, and academic perspectives, provides updated recommendations on acquiring and evaluating clinical and economic evidence to inform formulary and medical policy decisions. It also includes new guidance related to emerging special topic considerations such as biosimilars, specialty pharmacy products, and companion diagnostic tests. Version 4.0 has been modified to improve the usability of the Format, with clarifying guidance related to logistical considerations such as a recommended time frame for implementation of Version 4.0, as well as dossier updates and ongoing communication between manufacturers and health care decision makers. The Format should be used as a framework for ongoing evidencebased dialogue between manufacturers and payers. The evolving health care landscape will require new levels of collaboration and communication among key stakeholders to successfully navigate the challenges of this new environment. The Format provides a framework to support these critical interactions related to product value by facilitating an evidence-based, transparent approach.
UR - http://www.scopus.com/inward/record.url?scp=84969592866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969592866&partnerID=8YFLogxK
U2 - 10.18553/jmcp.2016.16071
DO - 10.18553/jmcp.2016.16071
M3 - Comment/debate
C2 - 27123906
AN - SCOPUS:84969592866
SN - 2376-0540
VL - 22
SP - 444
EP - 446
JO - Journal of Managed Care and Specialty Pharmacy
JF - Journal of Managed Care and Specialty Pharmacy
IS - 5
ER -